Loading...
The relationship between treatment adherence and risk for virologic failure has been well studied for nonnucleosidse reverse transcriptase inhibitor (NNRTI)-based and boosted protease inhibitor (PI)-based antiretroviral regimens but not for the more recently available integrase inhibitor–based ones. In a recent prospective cohort study, researchers examined patterns of adherence among HIV-infected patients receiving twice-daily raltegravir and the effect of these patterns on the development of drug resistance.
The 81 study participants had a mean age of 48, and 72% were men. At baseline, 12% were treatment naive, and 74% had viral loads <40 copies/mL; the median CD4 count was 468 cells/mm3. All the regimens being used had genotypic sensitivi…